Real-World Observational Study of Outcomes for Acute Myeloid Leukemia (AML) Patients Treated With Glasdegib or Venetoclax in US Community Oncology Practices

First published 25/09/2020

Last updated 14/03/2024

EU PAS number:

EUPAS37385

Study

Finalised

Documents

Study protocol

Initial protocol

B1371039 PFI_AML CRF_Study Protocol_Final_EUQPPV_11May2020

English (505.42 KB - PDF) View document

Study results

PFI_AML Glasdegib CRF_Final Report 20210207_vFinal_EU-PASS_Upload

English (1.11 MB - PDF) View document

Study report

Other information

Secondary tabs